Replies to post #246 on vTv Therapeutics Inc (VTVT)

[cjstocksup]

Do you have a link to the Analyst information on how the VTVT Azeliragon data will be presented? I do know about the different delivery method and the last trials showed promise.

According to Analysists-Upcoming Presentation Would Be Whole Different Thing Compared to Previous Ones!!
VTVT has been working on a different delivery method to refine the previous study and this different options could change
the way in which Alzheimer’s is treated. Load up this cheap shares as much as you can NOW, Once they release a final data
VTVT will hit $50~$100.

----------------------
vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
BUSINESS WIRE 10:30 AM ET 10/16/2018
Results of the Azeliragon Phase 3 STEADFAST Trial to be Presented during Oral Session

Subgroup Data Discussing the Effect of Azeliragon in Patients with Dementia and Diabetes to be Presented during Poster Session

HIGH POINT, N.C.--(BUSINESS WIRE)-- vTv Therapeutics Inc.(VTVT) , a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will deliver an oral presentation and present a poster at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference on October 24-27, 2018 in Barcelona, Spain.

The oral presentation will detail the results from the phase 3 STEADFAST study of azeliragon in patients with mild Alzheimer’s disease. Details of the oral presentation are listed below:

Oral Presentation Title: “Safety and efficacy results from the phase 3, multicenter, 18-month STEADFAST trial of azeliragon in patients with mild Alzheimer’s disease”

Date and Time: Fri., Oct. 26, 2018 at 3 p.m. CEST (9 a.m. EST)
In addition, a subgroup analysis from the company’s STEADFAST trial will be presented as a poster. Details of the poster presentation are listed below:

[cjstocksup]

VTVT with positive results could be worth $200.00. I was reading up on the new delivery method to get FDA approval for VTVT's Azeliragon under their new studies and I also found this, it was written yesterday. I think this could get VTVT alot of attention in the days ahead. It also describes what happened to the market cap of BIIB and the single day $12 billion increase in market cap for BIIB back in July when they announced positive phase 2 results.
Alzheon: A Bold And Novel Approach To Treating Alzheimer's With A Solid Chance Of Success

Oct. 22, 2018 6:11 PM ET

About: Alzheon (ALZH), Includes: AXON, BIIB, VTVT

[cjstocksup]

VTVT: findings from the STEADFAST study suggest that lower maximal plasma concentrations of azeliragon are associated with improvements in efficacy relative to placebo. These findings are consistent with published data from the phase 2b study (Burstein et al. BMC Neurology 2014, 14:12).

Relying upon the program’s Fast Track Designation status and study results to date, the Company will pursue expedited discussions with the Food and Drug Administration (FDA) to propose a pathway for further clinical development in support of regulatory approval of azeliragon.